Search results for " leukocyte"

showing 10 items of 364 documents

A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation.

2013

Thymidine phosphorylase (TYMP), an enzyme involved in nucleotide synthesis, has been implicated in critical biological processes such as DNA replication, protection against mutations, and tissue repair. In this work, we retrospectively evaluated the influence of a polymorphism in the TYMP gene (rs112723255; G/A) upon the outcome of 448 patients subjected to allogeneic stem cell transplantation (allo-SCT) from an human leukocyte antigen (HLA)-identical sibling donor. The TYMP genotype of patients correlated with overall survival—carriers of the minor allele (A) being at an increased risk of dying after transplantation (hazard ratio, HR = 1.9; P = 0.004). This effect was mostly due to differe…

OncologyAdultMalemedicine.medical_specialtyTime FactorsAdolescentGenotypeGraft vs Host DiseaseHuman leukocyte antigenDiseaseBiologyRisk FactorsInternal medicineGenotypemedicineHumansTransplantation HomologousAlleleChildAllelesAgedRetrospective StudiesThymidine PhosphorylasePolymorphism GeneticHistocompatibility TestingSiblingsHazard ratioInfantHematologyMiddle AgedMinor allele frequencyTransplantationSurvival RateChild PreschoolHematologic NeoplasmsImmunologyChronic DiseaseFemaleComplicationStem Cell TransplantationAmerican journal of hematology
researchProduct

P043 HLA-DPB matching and donor cytomegalovirus positive (CMV+) status: An “unconventional alliance” associated with a decreased relapse incidence in…

2017

Aim While the role of HLA-DPB1 (DP) compatibility in uHSCT regarding graft versus host disease (GVHD)- and graft versus leukaemia (GVL)-effects has been extensively discussed, its interaction with donor CMV status (dCMV), remains elusive. The aim of this study was, to investigate the impact of dCMV status in DP matched (DPM) and mismatched (DPMM) uHSCT. Methods 1749 HSCT transplant (Tx) pairs were DP genotyped with an exon 2 amplicon based NGS approach in order to assess their DP matching status. CMV sero-status as well as clinical data were retrieved from the German Stem Cell Registry. Overall survival (OS), relapse incidence (RI) and chronic GvHD (cGvHD) were defined as endpoints, while s…

OncologyCMV statusmedicine.medical_specialtybusiness.industryIncidence (epidemiology)medicine.medical_treatmentImmunologyGeneral MedicineHuman leukocyte antigenHematopoietic stem cell transplantationmedicine.disease3. Good healthGraft-versus-host diseaseStatistical significanceInternal medicineImmunologyImmunology and AllergyMedicinebusinessCytomegalovirus PositiveCohort studyHuman Immunology
researchProduct

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC…

2020

Introduction: Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarkers to these agents is lacking and multiple clinicopathological factors have been evaluated. The aim of this study was to analyze the potential role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels in patients with pretreated NSCLC receiving nivolumab. Methods: This was a retrospective multicenter study involving 14 Italian centers, evaluating the role of some laboratory results in patients with NSCLC treat…

OncologyMale030213 general clinical medicineLung NeoplasmsNeutrophilsLymphocytenon-small cell lung cancer (NSCLC)DiseaseNSCLCchemistry.chemical_compoundLeukocyte Count0302 clinical medicineAntineoplastic Agents ImmunologicalCarcinoma Non-Small-Cell LungPD-180 and overLeukocytesPharmacology (medical)LymphocytesNon-Small-Cell LungAged 80 and overbiologyGeneral MedicineMiddle AgedPrognosisImmunologicalmedicine.anatomical_structureNivolumab030220 oncology & carcinogenesisLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; Prognosis; Adult; Aged; Aged 80 and over; Antineoplastic Agents Immunological; Biomarkers; Carcinoma Non-Small-Cell Lung; Female; Humans; Leukocyte Count; Leukocytes; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Prognosis; Retrospective StudiesFemaleNivolumabAdultPD-L1medicine.medical_specialtyLDHAntineoplastic AgentsPLRNONLR03 medical and health sciencesPD-L1Lactate dehydrogenaseInternal medicinemedicineHumansNeutrophil to lymphocyte ratioAgedRetrospective Studiesbusiness.industryCarcinomamedicine.diseaseRheumatologychemistrybiology.proteinLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; PrognosisbusinessBiomarkers
researchProduct

Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment

2007

Abstract Pegylated interferon (PEG-IFN) in combination with ribavirin is the standard of treatment for chronic hepatitis C. Several viral and host factors influence the outcome of treatment, such as hepatitis C virus (HCV) genotype, baseline viral load, viral kinetics, race, body weight, advanced liver disease, HIV co-infection, and adherence to therapy. Monitoring the response of HCV to treatment during the early time points (4 weeks or 12 weeks) after initiation of therapy has emerged as a critical tool to predict sustained virologic response (SVR), defined as undetectable serum HCV RNA 24 weeks after the end of therapy. To counterbalance the influence of host and viral factors, treatment…

Oncologymedicine.medical_specialtyHepatitis C virusHuman leukocyte antigenInterferon alpha-2medicine.disease_causeAntiviral AgentsPolyethylene GlycolsLiver diseasechemistry.chemical_compoundChronic hepatitisPegylated interferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesDrug ToleranceHepatitis C Chronicmedicine.diseaseRecombinant ProteinsBlack or African AmericanTreatment OutcomechemistryVirologic responseImmunologybusinessViral loadmedicine.drugDigestive and Liver Disease
researchProduct

Predicted Indirectly reCognizable HLA epitopes (PIRCHE) are associated with poorer outcome after single mismatch unrelated donor stem cell transplant…

2019

There is no established standard for selection of mismatched unrelated donors. Indirect recognition of HLA mismatches can be predicted using the model of “Predicted Indirectly ReCognizable HLA Epitopes” (PIRCHE). We performed a multicenter retrospective study evaluating the impact PIRCHE on outcome after allogeneic stem cell transplantation (allo-HSCT) from single mismatched (HLA 9/10 matched) unrelated donors. The study cohort included 424 adult recipients of HLA 9/10 matched unrelated donor transplants (9/10 MUD), treated for AML or MDS at 6 transplant centers across Germany. Detection of PIRCHE was associated with lower overall survival (OS) (47 vs. 57%, <i>p</i> = 0.04), hig…

Oncologymedicine.medical_specialtyMultivariate analysisbusiness.industryIncidence (epidemiology)Retrospective cohort studyHematologyHuman leukocyte antigen030204 cardiovascular system & hematologyTransplantation03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureInternal medicineCohortmedicineImmunology and AllergyCumulative incidenceBone marrowbusiness030215 immunologyResearch Article
researchProduct

Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms

2021

High-grade Gastroenteropancreatic Neuroendocrine neoplasms (H-NENs) comprehend well-differentiated tumors (NET G3) and poorly differentiated carcinomas (NEC) with proliferative activity indexes as mitotic count (MC) &gt

Oncologymedicine.medical_specialtyMyeloidmyeloid markersT cellCD3gastroenteropancreatic neuroendocrine neoplasms; myeloid markers; tumor microenvironmentCD33PopulationHuman leukocyte antigenSettore MED/08 - Anatomia PatologicaArticleSurgical pathology03 medical and health sciences0302 clinical medicineInternal medicinemedicinetumor microenvironmenteducation030304 developmental biologymyeloid marker0303 health sciencesTumor microenvironmenteducation.field_of_studybiologybusiness.industryRGeneral Medicinegastroenteropancreatic neuroendocrine neoplasms myeloid markers tumor microenvironmentgastroenteropancreatic neuroendocrine neoplasmsstomatognathic diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisgastroenteropancreatic neuroendocrine neoplasmbiology.proteinMedicinebusiness
researchProduct

OR26. Investigating the impact of patient’s non-shared HLA-C Allotype expression levels in A 9/10 Single HLA-C mismatched hematopoieticstem cell tran…

2018

Aim Petersdorf et al. reported in 2014 an association between patient high expressed HLA-C (C) allotypes and inferior HSCT outcome using an imputed C-expression model (Apps et al., 2013). This study aims at: a) examining the validity of Apps et al. model in Caucasians by using the same methodology in a sample of 400 healthy German blood donors. b) specifically investigating the effect of patient’s non-shared (PNS) C expression levels on outcome by applying C expression imputed data in a 9/10 HLA C-mismatched HSCT setting. Methods Buffy coats from 400 healthy German blood donors were tested by flow cytometry as previously described (Apps et al., 2013) in order to determine C expression on ly…

Oncologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryImmunologyGeneral MedicineHuman leukocyte antigenAllotypeFlow cytometryCorrelationHLA-CAntigenInternal medicineStatistical significanceCohortImmunology and AllergyMedicinebusinessHuman Immunology
researchProduct

Genetic Variability in Selected ZnT8 SNPs in the Opolskie Voivodeship (Poland) - Relationship with Type 2 Diabetes and its Complications and Accompan…

2023

Introduction: Type-2 Diabetes Mellitus (DM2) is of multigeneous origin, and its course may be modified by autoimmune mechanisms. It can be assumed that the clinically different course of diabetes depends, among others, on the genetically determined efficiency of the mechanisms of zinc homeostasis maintenance. The study of the relationship of mutations in the gene encoding ZnT8 with the tendency to the occurrence of diabetes and its course may result in new therapeutic possibilities in the future. It is also interesting because in leukocytes only ZnT8 shows significant individual variability in expression under physiological and pathological conditions, which indicates its genetic determinan…

Opolskie voivodeship; Type-2 diabetes mellitus; Leukocytes; Obesity; Hypertension; StrokesJournal of Medicine and Public Health
researchProduct

SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage.

2011

Fibrosis results from inflammatory tissue damage and impaired regeneration. In the context of bleomycin-induced pulmonary fibrosis, we demonstrated that the matricellular protein termed secreted protein acidic and rich in cysteine (SPARC) distinctly regulates inflammation and collagen deposition, depending on its cellular origin. Reciprocal Sparc(-/-) and wild-type (WT) bone marrow chimeras revealed that SPARC expression in host fibroblasts is required and sufficient to induce collagen fibrosis in a proper inflammatory environment. Accordingly, Sparc(-/-) >WT chimeras showed exacerbated inflammation and fibrosis due to the inability of Sparc(-/-) macrophages to down-regulate tumor necrosis …

Pathologymedicine.medical_specialtyAnimals; Bleomycin; Bone Marrow Cells; Chimera; Collagen; Down-Regulation; Fibroblasts; Leukocytes; Macrophages; Mice; Mice Inbred BALB C; Osteonectin; Pneumonia; Pulmonary Fibrosis; Transforming Growth Factor beta; Tumor Necrosis Factor-alphaPulmonary FibrosisDown-RegulationInflammationBone Marrow CellsBiologyPathology and Forensic MedicineMiceFibrosisTumor necrosis factor productionTransforming Growth Factor betaPulmonary fibrosismedicineLeukocytesAnimalsOsteonectinInbred BALB CChimeraTumor Necrosis Factor-alphaMacrophagesMatricellular proteinRegular ArticleSPARCTransforming growth factor betaPneumoniaFibroblastsBLEOMYCINmedicine.diseaseSPARC; BLEOMYCIN; LUNG DAMAGELUNG DAMAGECancer researchbiology.proteinTumor necrosis factor alphaCollagenmedicine.symptomOsteonectin
researchProduct

Hepatocellular carcinoma after thorotrast exposure: establishment of a new cell line (Mz-Hep-1).

1985

A human hepatoma cell line, associated with thorotrast exposure, from an hepatitis B marker-negative patient was established as a permanent cell line (Mz-Hep-1) in tissue culture. Histology of the primary tumor, as well as phase contrast, transmission and scanning electron microscopy of the cultured cells showed typical characteristics of liver cells. Mz-Hep-1 cells secreted complement components (C2, C3, C4), carcinoembryonic antigen, lactate dehydrogenase, chymotrypsin, haptoglobin and retinol-binding protein and expressed HLA-, transferrin-, blood group B-related determinants and complement component C5 and carcinoembryonic antigen on their cell surface. Mz-Hep-1 cells represent the firs…

Pathologymedicine.medical_specialtyCarcinoma HepatocellularCellHuman leukocyte antigenCell Linechemistry.chemical_compoundTissue cultureCarcinoembryonic antigenLactate dehydrogenasemedicineHumansHepatitis B e AntigensHepatitis B Surface AntigensHepatologybiologyCell CycleLiver NeoplasmsAngiographyComplement System ProteinsCell cycleMiddle Agedmedicine.diseaseMolecular biologyCarcinoembryonic Antigenmedicine.anatomical_structurechemistryCell cultureHepatocellular carcinomaKaryotypingbiology.proteinMicroscopy Electron ScanningFemaleThorium Dioxidealpha-FetoproteinsHepatology (Baltimore, Md.)
researchProduct